How Bad Will the Stock Market Get?
In recent trading days, global stock markets have seen massive…
Sell
2
PLRX Quote, Financials, Valuation and Earnings
Last price:
$1.23
Seasonality move
:
-17.68%
Day range:
$1.21 - $1.36
52-week range:
$1.21 - $16.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.05x
P/B ratio:
0.25x
Volume:
1.7M
Avg. volume:
3M
1-year change:
-91.47%
Market cap:
$76.5M
Revenue:
$1.6M
EPS (TTM):
-$3.47
Analysts' Opinion
-
Consensus RatingPliant Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 11 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.06, Pliant Therapeutics has an estimated upside of 705% from its current price of $1.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $1.25.
Fair Value
-
According to the consensus of 12 analysts, Pliant Therapeutics has 705% upside to fair value with a price target of $10.06 per share.
PLRX vs. S&P 500
-
Over the past 5 trading days, Pliant Therapeutics has overperformed the S&P 500 by 1.84% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pliant Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pliant Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Pliant Therapeutics reported revenues of --.
Earnings Growth
-
Pliant Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Pliant Therapeutics reported earnings per share of -$0.82.
Enterprise value:
-249M
EV / Invested capital:
--
Price / LTM sales:
15.05x
EV / EBIT:
--
EV / Revenue:
-49.53x
PEG ratio (5yr expected):
--
EV / Free cash flow:
1.56x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $9.7M | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$127.2M | -$184.1M | -$228.4M | -$47M | -$53.3M | |
| EBITDA | -$120.7M | -$158.2M | -$205.2M | -$40.3M | -$48.4M | |
| Diluted EPS | -$2.97 | -$2.76 | -$3.47 | -$0.69 | -$0.82 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $290.8M | $209.4M | $340.3M | $505.5M | $362.3M | |
| Total Assets | $295.5M | $221.2M | $350.6M | $512.2M | $396.9M | |
| Current Liabilities | $11.6M | $16.8M | $23.9M | $28.5M | $33.2M | |
| Total Liabilities | $12.5M | $22.2M | $37.3M | $38.6M | $92.9M | |
| Total Equity | $283.1M | $199.1M | $313.3M | $473.6M | $304.1M | |
| Total Debt | -- | -- | $9.9M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$94.6M | -$116.4M | -$155.5M | -$25.1M | -$47.7M | |
| Cash From Investing | -$150.2M | -$127M | $140.3M | $31.9M | $39.1M | |
| Cash From Financing | $226.9M | $274.4M | $23.1M | $219K | $102K | |
| Free Cash Flow | -$96.4M | -$117.3M | -$159.4M | -$25.2M | -$47.9M | |
PLRX
Sector
Market Cap
$76.5M
$33.3M
Price % of 52-Week High
7.57%
39.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-91.47%
-47.95%
Beta (5-Year)
--
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.38
200-day SMA
Sell
Level
$10.68
Bollinger Bands (100)
Sell
Level
3.35 - 14.15
Chaikin Money Flow
Buy
Level
29.4M
20-day SMA
Sell
Level
$1.50
Relative Strength Index (RSI14)
Sell
Level
26.08
ADX Line
Sell
Level
50.93
Williams %R
Buy
Level
-90.9091
50-day SMA
Sell
Level
$4.16
MACD (12, 26)
Sell
Level
-0.71
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
37.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (15.6007)
Buy
CA Score
(Annual)
Level (-0.2452)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.3866)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Stock Forecast FAQ
In the current month, PLRX has received 1 Buy ratings 11 Hold ratings, and 0 Sell ratings. The PLRX average analyst price target in the past 3 months is $10.06.
-
Where Will Pliant Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pliant Therapeutics share price will rise to $10.06 per share over the next 12 months.
-
What Do Analysts Say About Pliant Therapeutics?
Analysts are divided on their view about Pliant Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pliant Therapeutics is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Pliant Therapeutics's Price Target?
The price target for Pliant Therapeutics over the next 1-year time period is forecast to be $10.06 according to 12 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is PLRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pliant Therapeutics is a Hold. 11 of 12 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of PLRX?
You can purchase shares of Pliant Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pliant Therapeutics shares.
-
What Is The Pliant Therapeutics Share Price Today?
Pliant Therapeutics was last trading at $1.23 per share. This represents the most recent stock quote for Pliant Therapeutics. Yesterday, Pliant Therapeutics closed at $1.25 per share.
-
How To Buy Pliant Therapeutics Stock Online?
In order to purchase Pliant Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is JOBY Stock a Buy, Sell or Hold?
Joby Aviation (NYSE:JOBY) got started with the big idea of…
Why Did Tesla Stock Fall So Sharply?
Tesla (TSLA) stock has often gone against the grain. It…
Stock Ideas
Sell
37
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
20
Is AAPL Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 29x
Sell
33
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 33x
Alerts
Sell
24
FNGA alert for Apr 8
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 1.93% over the past day.
Buy
75
SOXS alert for Apr 8
Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 11.22% over the past day.
Buy
82
TECS alert for Apr 8
Direxion Daily Technology Bear 3x Shares [TECS] is up 5.94% over the past day.
